Globe Newswire
Globe Newswire
More Globe Newswire
View Older Stories View Newer Stories-
Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose
-
FDA approves Roche’s Gazyva/Gazyvaro for the treatment of lupus nephritis
-
Marko Law Firm Further Expands Reach Across Michigan with Aggressive Advocacy in Personal Injury Litigation
-
Latest helicopter tech to be showcased at expo in north China's Tianjin
-
Latest helicopter tech to be showcased at expo in north China's Tianjin
-
Levitask Announces Patent-Pending T-Mech Mechanism, Introducing Elevated Seating for the Modern Workspace
-
ServiceTrade Launches “Grow Your Own” Technician Workforce Program with VSC Fire & Security and Durham Tech
-
WePlay x Care Bears Halloween Carnival Party Officially Kicks Off!
-
Ryoncil® Net Revenues Increase 69% in Second Quarter Post Launch
-
Faraday Future Founder and Co-CEO YT Jia Shares Weekly Investor Update: The Whole FX Team is Now in Full Sprint Mode for the Year-End Off-Line Target for the Company’s First FX Super One Vehicle
-
Kering and L’Oréal forge an alliance in beauty and wellness
-
Vantage Drilling International Ltd. – Announcement of Contract Termination
-
Nexzen Extracts — The Best THCA Brand Launches Spooky Halloween Sale with Up to 45% Off Sitewide
-
Rockcliffe Labs Launches Canada’s First Venture-Building Platform for Biotechnology and Life Sciences with Mission to Create 100 Companies
-
PSMAddition data show Novartis Pluvicto™ delays progression to end-stage prostate cancer
-
Avacta Therapeutics Presents Compelling Phase 1a Data for Faridoxorubicin and the pre|CISION® Platform at the European Society of Medical Oncology Annual Congress
-
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
-
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
-
Mutuum Finance (MUTM) Progresses Toward Q4 2025 Testnet Launch With $17.6 Million Raised
-
FBS AI Assistant Helps Traders Skip Market Noise and Focus on Strategy
-
Arbrest Champions Sustainability with Solid Wood Furniture That Extends the Life of Trees
-
Crypto News (Live): From $0.0075 to $0.50? Blazpay’s AI Presale Heats Up as Solana and BNB Investors Seek New Gains
-
Sify Technologies to announce Financial Results for Second Quarter FY 2025-26 on Saturday, October 25, 2025
-
Crosby Brownlie Expands its Syracuse Location to Support Regional Growth
-
Maple Financial Announces Strategic Equity Investment from Nesto Group via CMLS
-
BexBack Launches No KYC, 100x Leverage, and $50 Welcome Bonus for Easy Crypto Futures Trading!
-
Nasdaq Halts Platinum Analytics Cayman Limited
-
Nasdaq Halts Etoiles Capital Group Co., Ltd.
-
Nasdaq Halts Pitanium Limited
-
Astra Bitcoin: Dr. Antoun Toubia Launches a Revolutionary Asset-Backed Ecosystem Built on Ethereum
-
DeFi crypto Mutuum Finance (MUTM) Onboards Over 17,300 Investors With 70% of Phase 6 Allocated
-
NuCana Presents Encouraging Data on NUC-7738 in Combination with PD-1 Inhibitors using Primary Patient-Derived Organoids and Autologous Tumor-Infiltrating Lymphocytes at the ESMO Congress 2025
-
Reconstruction and Opportunities: The CDFG Consumer White Paper 2024-2025 is Released
-
Precede Biosciences Presents New ESMO 2025 Data Demonstrating Its Liquid Biopsy Platform’s Ability to Resolve Target Expression and Molecular Subtypes in Small Cell Lung Cancer
-
Newfoundland and Labrador Victims and Survivors of Alcohol and Drug-Related Crashes Remembered at MADD Canada’s Annual Memorial Monument Ceremony
-
ITM Announces Phase 3 COMPETE Data Demonstrating a Statistically Significant Higher Objective Response Rate with n.c.a. 177Lu-edotreotide (ITM-11) vs. Everolimus in Patients with Gastroenteropancreati
-
Celcuity Presents Updated Data at the 2025 ESMO Congress from Phase 1 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration Resistant Prostate Cancer (“mCRPC”)
-
Celcuity Provides Update on Status of the PIK3CA Mutated Cohort of Phase 3 VIKTORIA-1 Trial and Releases Additional Data Analysis From Phase 1b Clinical Trial
-
Detailed Results from PIK3CA Wild-Type Cohort of Phase 3 VIKTORIA-1 Trial Presented at 2025 ESMO Congress Demonstrate Potential for Gedatolisib Regimens to be Practice Changing for Patients with HR+/
-
Kura Oncology Announces Preliminary Data from Its Farnesyl Transferase Inhibitor (FTI) Programs at the 2025 European Society for Medical Oncology (ESMO) Congress
-
Corbus Pharmaceuticals Presents CRB-701 Robust Clinical Responses in HNSCC and Cervical Cancers at ESMO25
-
Blazpay’s Phase 2 of Crypto Presale Surges With Over $250,000 Raised as XRP and Bitcoin Consolidate
-
Nurix Therapeutics Reports New Clinical Data from First-in-Class Oral CBL-B Inhibitor, NX-1607, Demonstrating Single-Agent Activity Across Multiple Tumor Types at the European Society for Medical Onco
-
General Oncology Announces Promising Preliminary Phase 1 Results from SHARON Trial Presented at ESMO 2025
-
Olema Oncology Announces New Data from the Phase 1b/2 Trial of Palazestrant Plus Ribociclib in ER+/HER2- Metastatic Breast Cancer at ESMO 2025
-
AdvanCell’s 212Pb-ADVC001 demonstrates encouraging safety and compelling anti-tumor activity in Phase 1b in prostate cancer
-
Roche’s phase III evERA data showed giredestrant significantly improved progression-free survival in people with ER-positive advanced breast cancer
-
Piazza Garibaldi Introduces End-to-End Project Management for Ultra-Luxury Living and Yachting
-
Westhaven Gold Provides Corporate Update
-
Aeroméxico Announces Filing of Amended Registration Statement for Proposed Global Offering
